Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential
- Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics
- Nektar Therapeutics Reports 2024 Financial Progress
- Nektar reports Q4 adjusted EPS (15c), consensus (19c)
- Nektar completes enrollment in REZOLVE-AA Phase 2b trial of rezpegaldesleukin